Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isa Mambetsariev

Showing results (1-10 of 78) with videos related to

Pageof 8
Sort By:
BMC Cancer|August 3, 2016
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancerBrian Won, Isa Mambetsariev, Ravi Salgia
Chest|October 9, 2021
ResponseMoom R Roosan, Isa Mambetsariev, Ravi Salgia
Cold Spring Harbor Molecular Case Studies|December 18, 2020
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring <i>MET</i> exon 14 mutation: a research reportKatherine G Roth, Isa Mambetsariev, Ravi Salgia
Future Oncology (London, England)|February 17, 2018
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancerIdoroenyi Amanam, Rohan Gupta, Isa Mambetsariev, et al.
Journal of Thoracic Disease|November 4, 2020
Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequenceRebecca Pharaon, Isa Mambetsariev, Jeremy Fricke, et al.
JCO Oncology Practice|July 10, 2020
Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?Idoroenyi Amanam, Isa Mambetsariev, Rohan Gupta, et al.
Trends in Molecular Medicine|July 23, 2019
The Mitochondrion as an Emerging Therapeutic Target in CancerKatherine G Roth, Isa Mambetsariev, Prakash Kulkarni, et al.
BMC Cancer|March 23, 2018
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsyIsa Mambetsariev, Lalit Vora, Kim Wai Yu, et al.
Cell Reports. Medicine|February 1, 2021
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Value-Based Medicine and Integration of Tumor BiologyGabriel A Brooks, Linda D Bosserman, Isa Mambetsariev, et al.
Pageof 8

Showing results (1-10 of 78) with videos related to

Sort By:
Pageof 8
BMC Cancer|August 3, 2016
Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancerBrian Won, Isa Mambetsariev, Ravi Salgia
Chest|October 9, 2021
ResponseMoom R Roosan, Isa Mambetsariev, Ravi Salgia
Cold Spring Harbor Molecular Case Studies|December 18, 2020
Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring <i>MET</i> exon 14 mutation: a research reportKatherine G Roth, Isa Mambetsariev, Ravi Salgia
Future Oncology (London, England)|February 17, 2018
The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancerIdoroenyi Amanam, Rohan Gupta, Isa Mambetsariev, et al.
Journal of Thoracic Disease|November 4, 2020
Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequenceRebecca Pharaon, Isa Mambetsariev, Jeremy Fricke, et al.
JCO Oncology Practice|July 10, 2020
Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?Idoroenyi Amanam, Isa Mambetsariev, Rohan Gupta, et al.
Trends in Molecular Medicine|July 23, 2019
The Mitochondrion as an Emerging Therapeutic Target in CancerKatherine G Roth, Isa Mambetsariev, Prakash Kulkarni, et al.
BMC Cancer|March 23, 2018
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsyIsa Mambetsariev, Lalit Vora, Kim Wai Yu, et al.
Cell Reports. Medicine|February 1, 2021
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 1, 2017
Value-Based Medicine and Integration of Tumor BiologyGabriel A Brooks, Linda D Bosserman, Isa Mambetsariev, et al.
Pageof 8